Business Wire

Momcozy Debuts in the European Market at the Baby Show


Momcozy (“the Company”), a leading maternity and baby brand with a focus on moms’ needs, attended the Baby Show with Lidl GB (“the Baby Show”), hosted at ExCel London March 3-5, 2023. The Baby Show is one of the largest pregnancy, baby, and parenting events in the UK, and has been helping new and expectant parents find everything they need for their growing families since 2002. With several stops around the UK planned for the year, the Baby Show in London allowed Momcozy to introduce themselves to the European market, which they have recently entered, and promote their products made for babies and mothers.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Momcozy Debuts in the European Market at the Baby Show (Photo: Business Wire)

As part of their introduction to British consumers, Momcozy showed off an assortment of pumps, pump accessories, pumping bra and other maternity-inspired products to the delight of parents. Along with handing out free milk storage bags and showcasing cutting-edge products like their Warming and Vibration Lactation Massager, Momcozy centred their stand at M61 around their most popular innovation, the S12 Pro Breast Pump.

“Our goal as a company has always been to support mothers in their parenting journey. So whether it’s a wearable breast pump, or a pumping bra all recognizes mom’s voices, as the product’s development came about from their input,” said Ella, Marketing Manager of Momcozy.

Momcozy 4-in-1 pumping bra has been a game-changer for breastfeeding moms since its launch in 2022, with several moms on Amazon praising the bra's versatility and security with different kinds of pumps, as well as its comfortable and supportive fit. According to customer feedback, the bra’s design is a particularly good fit with Momcozy’s wearable breast pumps, fitting snugly without too much pressure for a better lactation experience.

Another flagship product of Momcozy, the S12 Pro, also attracted a lot of attention at the Baby Show. Following detailed interviews with the Momcozy community, the Company developed this new, hands-free pump series with an eye toward comfort for moms. Boasting single or double pump options, the S12 Pro comes with an updated double-sealed flange design that fits more snugly to offer moms a more efficient, soft suction pumping experience that also helps them avoid leakage.

“Also, we recently announced the year-long ‘Parachute Care Program’ to support more moms' breastfeeding journeys, and hope that we will be a companion for more moms in Europe,” Ella said.

In addition to the Program, Momcozy is offering a 25% off for breast pump orders to moms who work in specific professions to celebrate International Women’s Day. Moms in Europe can shop through Amazon or Momcozy website.

Following their introduction to the UK and other European countries at the Baby Show in London, Momcozy will also participate at the event’s stop at NEC Birmingham May 12-14, 2023.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Marketing Dept.
Ella Zheng
1-855-322-1777 (Mon.-Fri. 8:30am-12:00pm; 1:00pm-5:30pm PST)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 19:18:00 EEST | Press release

REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 19:00:00 EEST | Press release

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 17:09:00 EEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine

Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 16:11:00 EEST | Press release

As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke

Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 12:59:00 EEST | Press release

Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom